A diagnostics company is relocating its operations downtown and it has plans to greatly increase its workforce after the move.
Health care
HDL creditors call for investigation into reported insider payments
With reported shareholder payments and sales commissions allegedly totaling some $339 million, a group of creditors has asked for court permission to launch an investigation that could potentially unearth money owed to the Chapter 11 estate.
HDL buyer to dissolve brand
The Health Diagnostic Laboratory name that was once a point of pride for the Richmond startup scene will eventually vanish under new ownership. But the firm will continue to operate downtown, and a portion of its workforce will hold onto their jobs.
Judge approves $37M sale of HDL
With very little courtroom drama, HDL was given the OK on Wednesday to sell the bulk of its assets to a Texas lab company.
VCU Health unites under new flag
The health system is rebranding in hopes of bringing together all of its distinct operations under a more cohesive banner.
Connecting the dots between HDL and its buyer
A Texas company is ready to close a $37 million deal to buy HDL. But the two companies’ paths and key players have overlapped in the past – and in relation to the sales techniques that put HDL under the Justice Department’s microscope.
HDL founder entangled in insurer lawsuit
HDL co-founder Tonya Mallory has another major legal battle to face as an insurance firm that previously sued HDL expands its suit to include her as a defendant.
Senior living center rising in Chesterfield
One of many companies to recently tap into the senior living market is moving along with work on Huguenot Road, where it has plans for a 60-bed facility.
Financing deal paves way for HDL sale
With its $12M financing deal approved in court, bankrupt Health Diagnostic Laboratory is looking ahead to the looming auction of its business and assets.
Biotech firm maneuvers for better spot on stock market
With a recent capital raise giving a $13 million cushion, a downtown bioscience company completed a 1-for-50 reverse stock split in hopes of moving up in the stock market ranks and drawing more funding for clinical trials.